Src activity increases and Yes activity decreases during mitosis of human colon carcinoma cells.
Src and Yes protein-tyrosine kinase activities are elevated in malignant and premalignant tumors of the colon. To determine whether Src activity is elevated throughout the human colon carcinoma cell cycle as it is in polyomavirus middle T antigen- or F527 Src-transformed cells, and whether Yes activity, which is lower than that of Src in the carcinoma cells, is regulated differently, we measured their activities in cycling cells. We observed that the activities of both kinases were higher throughout all phases of the HT-29 colon carcinoma cell cycle than in corresponding phases of the fibroblast cycle. In addition, during mitosis of HT-29 cells, Src specific activity increased two- to threefold more, while Yes activity and abundance decreased threefold. The decreased steady-state protein levels of Yes during mitosis appeared to be due to both decreased synthesis and increased degradation of the protein. Inhibition of tyrosine but not serine/threonine phosphatases abolished the mitotic activation of Src. Mitotic Src was phosphorylated at novel serine and threonine sites and dephosphorylated at Tyr-527. Two cellular proteins (p160 and p180) were phosphorylated on tyrosine only during mitosis. Tyrosine phosphorylation of several other proteins decreased during mitosis. Thus, Src in HT-29 colon carcinoma cells, similar to Src complexed to polyomavirus middle T antigen or activated by mutation at Tyr-527, is highly active in all phases of the cell cycle. Moreover, Src activity further increases during mitosis, whereas Yes activity and abundance decrease. Thus, Src and Yes appear to be regulated differently during mitosis of HT-29 colon carcinoma cells.
Park
J
J
Department of Medicine, Stanford University, California 94305, USA.
Cartwright
C A
CA
D016590:Aphidicolin / Q000494:pharmacology; D000081247:CSK Tyrosine-Protein Kinase; D003110:Colonic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D004257:DNA Polymerase II / Q000037:antagonists & inhibitors; D016195:G2 Phase / Q000235:genetics / Q000502:physiology; D006801:Humans; D008938:Mitosis / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D015739:Nocodazole / Q000494:pharmacology; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors; D010766:Phosphorylation; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D051575:Proto-Oncogene Proteins c-yes; D014407:Tumor Cells, Cultured; D019061:src-Family Kinases
D011518:Proto-Oncogene Proteins; D016590:Aphidicolin; D011505:Protein-Tyrosine Kinases; D000081247:CSK Tyrosine-Protein Kinase; D051575:Proto-Oncogene Proteins c-yes; D019061:src-Family Kinases; C000631346:CSK protein, human; D004257:DNA Polymerase II; D010749:Phosphoprotein Phosphatases; D017027:Protein Tyrosine Phosphatases; D015739:Nocodazole